Akoya Biosciences (AKYA, Financial) has introduced a new assay aimed at enhancing the development of antibody-drug conjugates specifically for breast cancer treatment. This innovative assay is set to be highlighted at the upcoming American Association for Cancer Research (AACR) 2025 Annual Meeting in Chicago, Illinois, from April 25 to April 30.
The new assay will be showcased alongside real-world data generated by customers utilizing Akoya's PhenoCode Discovery IO60 panel, the company's leading ultrahigh-plex immuno-oncology platform. This development underscores Akoya's commitment to advancing cancer research and providing cutting-edge tools for the scientific community.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for Akoya Biosciences Inc (AKYA, Financial) is $2.99 with a high estimate of $5.00 and a low estimate of $1.65. The average target implies an upside of 135.43% from the current price of $1.27. More detailed estimate data can be found on the Akoya Biosciences Inc (AKYA) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, Akoya Biosciences Inc's (AKYA, Financial) average brokerage recommendation is currently 3.0, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Akoya Biosciences Inc (AKYA, Financial) in one year is $5.22, suggesting a upside of 311.02% from the current price of $1.27. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Akoya Biosciences Inc (AKYA) Summary page.
